NCT02885506View on ClinicalTrials.gov

A FIH Study to Investigate the Safety, Tolerability and PK of P218

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 24, 2016

Primary Completion Date

December 4, 2017

Study Completion Date

December 4, 2017

Conditions
Malaria
Interventions
DRUG

Oral administration of P218 capsules

Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

DRUG

Oral administration of P218 matching placebo

Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.

Trial Locations (1)

CR7 7YE

Richmond Pharmacology Ltd, Croydon

All Listed Sponsors
collaborator

Richmond Pharmacology Limited

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT02885506 - A FIH Study to Investigate the Safety, Tolerability and PK of P218 | Biotech Hunter | Biotech Hunter